Login to Your Account



Clinic Roundup


Monday, June 25, 2012
• Genkyotex SA, of Geneva, said it completed a Phase Ia study showing that GKT137831 , an inhibitor of NOX1 and NOX4 enzymes, is safe and well tolerated following oral administration of single doses in 36 healthy subjects.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription